Increased risk of hematologic malignancies in primary immunodeficiency disorders: opportunities for immunotherapy

Dorit Verhoeven, Arie Jan Stoppelenburg, Friederike Meyer-Wentrup, Marianne Boes

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

24 Citaten (Scopus)

Samenvatting

Primary immunodeficiency disorders (PIDs) convey increased susceptibility to infections and sometimes to malignancies, particularly lymphomas. Such cancer development can be contributed by immune impairments resulting in weakened immunological surveillance against (pre)malignant cells and oncogenic viruses. Molecular defects in PID-patients are therefore being clarified, identifying new targets for innovative immunotherapy. Particularly pediatric cancers are being scrutinized, where over one-third of cancer-related deaths are accounted for by leukemia and lymphomas. Here we review how immunopathogenic mechanisms of several PIDs might associate with lymphoma development. We furthermore delineate existing immunotherapy strategies in adults for potential therapeutic application in childhood leukemia and lymphomas.

Originele taal-2Engels
Pagina's (van-tot)22-31
Aantal pagina's10
TijdschriftClinical Immunology
Volume190
DOI's
StatusGepubliceerd - mei 2018

Vingerafdruk

Duik in de onderzoeksthema's van 'Increased risk of hematologic malignancies in primary immunodeficiency disorders: opportunities for immunotherapy'. Samen vormen ze een unieke vingerafdruk.

Citeer dit